Results 11 to 20 of about 3,861 (173)

Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients

open access: yesJournal of the Formosan Medical Association, 2010
Sevelamer hydrochloride is a recently developed phosphate binder, which is a quaternary amine anion exchanger without calcium or aluminum. Sevelamer is effective in controlling hyperphosphatemia without increasing the calcium load in chronic hemodialysis
Yu-Feng Lin   +13 more
doaj   +3 more sources

Sevelamer-associated ischemic colitis with perforation

open access: yesGastroenterology Insights, 2015
We present a case of an 83-year-old woman with end-stage renal disease and hyperphosphatemia treated with sevelamer carbonate, who underwent subtotal colectomy for diffuse bowel necrosis and two perforations in the transverse colon.
Rachel Hudacko, Peter Kaye
doaj   +2 more sources

Sevelamer Carbonate Crystal-Induced Colitis

open access: yesCase Reports in Gastrointestinal Medicine, 2020
Hyperphosphatemia is a common and well-described complication of end-stage renal disease. Despite strict dietary constraints and compliance, phosphate binders such as calcium acetate and/or sevelamer carbonate are also needed to treat secondary ...
T. Lai   +3 more
doaj   +2 more sources

Emerging Effects of Sevelamer in Chronic Kidney Disease

open access: yesKidney & Blood Pressure Research, 2013
Sevelamer, a non-absorbable anion exchange resin, is used to control hyperphosphatemia in chronic kidney disease (CKD) by binding to dietary phosphate in the gastrointestinal tract.
Ryota Ikee   +4 more
doaj   +2 more sources

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

open access: yesTherapeutics and Clinical Risk Management, 2008
Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri11Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital ...
Vincenzo Savica   +4 more
doaj   +2 more sources

Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China [PDF]

open access: yesTherapeutics and Clinical Risk Management, 2015
Lin Meng,1,2 Bin Fu1 1Department of Nephrology, Second Affiliated Hospital to Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Tianjin University of Traditional Chinese Medicine, Tianjin, People’s ...
Meng L, Fu B
doaj   +1 more source

Case report: Sevelamer-associated colitis—a cause of pseudotumor formation with colon perforation and life-threatening bleeding [PDF]

open access: yesFrontiers in Medicine, 2023
Chronic kidney disease (CKD) is a very common chronic non-communicable disease. Phosphate and calcium metabolism disorders are one of the most common features of CKD.
Margareta Fistrek Prlic   +13 more
doaj   +2 more sources

Use of sevelamer in chronic kidney disease: beyond phosphorus control

open access: yesNefrología (English Edition), 2015
Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease (CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational studies and clinical trials have shown that sevelamer has pleiotropic effects ...
Laura Rodríguez-Osorio   +6 more
doaj   +2 more sources

Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients

open access: yesInternational Journal of Nephrology and Renovascular Disease, 2014
Shahrzad OssarehDepartment of Medicine, Nephrology Section, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, IranAbstract: Phosphate control is still a great challenge in chronic kidney disease (CKD), and in spite of the great ...
Ossareh S
doaj   +1 more source

Extensive Parenchymal Brain Calcification in a Patient With Autosomal Dominant Polycystic Kidney Disease and Stage 5 Chronic Kidney Disease [PDF]

open access: yesClin Case Rep
ABSTRACT Extensive parenchymal brain calcification is uncommon in chronic kidney disease (CKD): intracranial vascular calcification affects up to 10% of uremic patients, but widespread Fahr‐type parenchymal deposits are rare and, where reported, have occurred in patients with a coexisting hypoparathyroid or parathyroid‐hormone (PTH)‐resistant state. We
Khan N, Streicher N.
europepmc   +2 more sources

Home - About - Disclaimer - Privacy